# Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

> **NCT06630416** · PHASE2 · RECRUITING · sponsor: **Northwestern University** · enrollment: 64 (estimated)

## Conditions studied

- Metastatic Bladder Urothelial Carcinoma
- Metastatic Malignant Solid Neoplasm
- Stage IV Bladder Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT06630416
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-27
- **Primary completion:** 2029-05-10
- **Final completion:** 2030-05-10
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06630416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06630416, "Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06630416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*